Last reviewed · How we verify
GS3-007a dry suspension
GS3-007a dry suspension is a small molecule drug that targets the SGLT2 receptor.
GS3-007a dry suspension is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | GS3-007a dry suspension |
|---|---|
| Also known as | GS3-007a |
| Sponsor | Changchun GeneScience Pharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
GS3-007a dry suspension works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is particularly useful for treating type 2 diabetes. By inhibiting SGLT2, GS3-007a dry suspension helps to decrease glucose levels in the blood, which can help to prevent complications associated with diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
- A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults (PHASE1)
- A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD) (PHASE1, PHASE2)
- A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GS3-007a dry suspension CI brief — competitive landscape report
- GS3-007a dry suspension updates RSS · CI watch RSS
- Changchun GeneScience Pharmaceutical Co., Ltd. portfolio CI